comparemela.com

Latest Breaking News On - Susanne embleton - Page 6 : comparemela.com

Pharming Group to Present at BioCapital Europe 2021

Pharming Group to Present at BioCapital Europe 2021 News provided by 11 Mar, 2021, 06:00 GMT LEIDEN, The Netherlands, March 11, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021. BioCapital Europe, organized by LSP, is Europe s premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe. The Company s presentation will be available following the event on its website at www.pharming.com 

Pharming Group reports financial results for full year 2020

Pharming Group reports financial results for full year 2020
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program navigateAPDS in US and Canada

Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program navigateAPDS in US and Canada
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs

Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs Costs for conversion of Ordinary Shares into ADS s waived by JP Morgan Chase for initial four weeks after today LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today separately announced that in connection with the listing of American Depositary Shares ( ADSs ) representing ordinary shares of nominal value of €0.01 each in the capital of the Company ( Ordinary Shares ) on the Nasdaq Global Market ( Nasdaq ), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs will begin tra

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.